Get the Stockscreener App
1.65
7.30%
-0.13
After Hours:
1.69
0.04
+2.42%
Indaptus Therapeutics Inc stock is traded at $1.65, with a volume of 66,636.
It is down -7.30% in the last 24 hours and down -47.62% over the past month.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
See More
Previous Close:
$1.78
Open:
$1.7899
24h Volume:
66,636
Relative Volume:
0.12
Market Cap:
$3.70M
Revenue:
-
Net Income/Loss:
$-15.42M
P/E Ratio:
-0.8967
EPS:
-1.84
Net Cash Flow:
$-13.41M
1W Performance:
+6.45%
1M Performance:
-47.62%
6M Performance:
-79.98%
1Y Performance:
+120.44%
1-Day Range:
$1.62
$1.7899
1-Week Range:
$1.52
$1.90
52-Week Range:
$0.2701
$13.40
Indaptus Therapeutics Inc Stock (INDP) Company Profile
Name
Indaptus Therapeutics Inc
Sector
Industry
Phone
(646) 427-2727
Address
3 COLUMBUS CIRCLE, NEW YORK
Compare INDP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDP
Indaptus Therapeutics Inc
|
1.65 | 3.99M | 0 | -15.42M | -13.41M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Indaptus Therapeutics Inc Stock (INDP) Latest News
Indaptus Therapeutics Reprices Warrants to Bolster Shareholder Support - TipRanks
Indaptus Therapeutics Signs Multiple Material Agreements - TradingView
Can Indaptus Therapeutics Inc. stock reach $100 price targetJuly 2025 Setups & Weekly High Potential Alerts - mfd.ru
Published on: 2026-02-04 21:21:37 - baoquankhu1.vn
Is Indaptus Therapeutics Inc.’s ROE strong enough2025 Top Decliners & Target Return Focused Picks - mfd.ru
Retail Trends: Why is Indaptus Therapeutics Inc stock going down2025 Earnings Impact & Free High Return Stock Watch Alerts - baoquankhu1.vn
Update Recap: Whats next for Indaptus Therapeutics Inc stock2025 EndofYear Setup & Expert Approved Trade Ideas - baoquankhu1.vn
Insider Trends: Why is Indaptus Therapeutics Inc stock going up2025 Support & Resistance & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Indaptus Therapeutics adjusts executive salaries and board member rescinds resignation - Investing.com India
Indaptus Therapeutics cuts executive pay, director stays on - TipRanks
Indaptus Therapeutics adjusts executive salaries and board member rescinds resignation By Investing.com - Investing.com South Africa
Indaptus Therapeutics Announces Board Member Decision - TradingView — Track All Markets
Analysis Recap: Is Indaptus Therapeutics Inc stock a buy or sellPortfolio Growth Summary & Low Risk High Win Rate Picks - baoquankhu1.vn
MACD Signal: Is Indaptus Therapeutics Inc stock a good pick for beginnersEarnings Trend Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Will Indaptus Therapeutics Inc. stock recover faster than marketFit and Size Notes & lightweight options for faster days - ulpravda.ru
Indaptus Therapeutics Appoints David Natan to Board - The Globe and Mail
Indaptus Therapeutics appoints David Natan to board and audit committee By Investing.com - Investing.com Australia
Indaptus Therapeutics appoints David Natan to board and audit committee - Investing.com
Will Indaptus Therapeutics Inc. stock reach Wall Street targetsJuly 2025 Technicals & Entry Point Confirmation Alerts - Улправда
How analysts rate Indaptus Therapeutics Inc. stock todayEarnings Risk Report & Weekly Hot Stock Watchlists - Улправда
Why did INDP stock gain 12% today? - MSN
Indaptus Therapeutics announces upcoming board leadership transition - MSN
Three Indaptus Therapeutics board members signal planned resignations By Investing.com - Investing.com Nigeria
Three Indaptus Therapeutics board members signal planned resignations - Investing.com
Indaptus Therapeutics Announces Board Resignations - TradingView — Track All Markets
Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Up 25.9% in December - Defense World
Indaptus Therapeutics looks to raise $2.25M in private placement - MSN
Biotech Stocks To Keep An Eye OnDecember 24th - MarketBeat
Indaptus Therapeutics Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar - marketscreener.com
Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar - The Globe and Mail
Indaptus Therapeutics secures $6 million investment, names new chairman By Investing.com - Investing.com Nigeria
Why Did INDP Stock Gain 12% Today? - Stocktwits
Indaptus Therapeutics stock falls after $6 million securities deal By Investing.com - Investing.com Nigeria
Indaptus Therapeutics stock falls after $6 million securities deal - Investing.com
Penny Stocks Worth Watching – December 25th - Defense World
What Does the Market Think About Indaptus Therapeutics Inc? - Benzinga
Indaptus Therapeutics Inc. (INDP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Indaptus Therapeutics Inc.: Are They Ready for Takeoff? - StocksToTrade
Indaptus Therapeutics, Inc.Common Stock (Nasdaq:INDP) Stock Quote - FinancialContent
Is It Too Late to Buy INDP Stock? - timothysykes.com
Indaptus Therapeutics (INDP) Stock in Focus on Dec. 24, 2025: $6M Financing, Leadership Reset, and the Dilution Question - ts2.tech
Indaptus Therapeutics Inc Stock (INDP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):